-
Anti-RPS6 Antibody Workflows for PDAC Research
2026-09-10
Use the Anti-RPS6 (7B10) Mouse Monoclonal Antibody to connect protein abundance with ribosome biogenesis, biosynthetic growth, and proliferation in pancreatic cancer models. The workflow combines Western blot, ICC/IF, and immunoprecipitation so researchers can distinguish total RPS6 changes from phosphorylation-specific signaling.
-
Epoxomicin and the Next Logic of Proteostasis
2026-09-10
Epoxomicin offers translational researchers a precise way to perturb proteasomal protein degradation and connect catalytic inhibition with ER stress, inflammation, neurodegeneration, and cellular fate. This thought-leadership guide integrates mechanistic evidence on UBR1 and UBR2 with practical assay design, product-selection logic, and responsible interpretation beyond conventional product-page claims.
-
Bafilomycin C1 in High-Content Cell Assays
2026-09-09
Bafilomycin C1 is a vacuolar H+-ATPases inhibitor that can convert lysosomal acidification into a measurable phenotypic perturbation. This article explains how to integrate that mechanism with high-content imaging, autophagy assay design, and iPSC-derived cardiomyocyte screening without confusing phenotype with mechanism.
-
Carbapenemase Spread in Enterobacter cloacae
2026-09-09
Chen et al. integrate carbapenemase gene localization, plasmid-transfer testing, antimicrobial susceptibility, mobile-element analysis, and strain genotyping across eight teaching hospitals in Guangdong. Their findings identify plasmid-associated blaNDM-1 as a major transmission concern and show why CREC surveillance must distinguish horizontal gene transfer from clonal dissemination.
-
Biotin-XX Tyramide Reagent Workflow Guide
2026-09-08
Biotin-XX Tyramide Reagent combines HRP-triggered signal amplification with membrane-impermeant surface labeling for sensitive IHC, ISH, and proximity-proteomics workflows. This guide translates the reagent’s chemistry and serotonin-specific interference findings into practical setup, optimization, and troubleshooting decisions.
-
HA-LNP PTEN mRNA for Transdermal Melanoma Therapy
2026-09-08
The reference study develops a hyaluronate-conjugated lipid nanoparticle that delivers PTEN mRNA through the skin and targets CD44-expressing melanoma cells. Its findings connect localized tumor suppressor restoration with immunogenic cell death, immune activation, and tumor growth suppression, while highlighting formulation and translational questions for mRNA-based cancer research.
-
TPPU: A Causal Framework for sEH Assays
2026-09-07
TPPU is a potent soluble epoxide hydrolase inhibitor for dissecting fatty acid epoxide signaling, inflammation, and osteoclast biology. This article presents a tiered assay strategy that separates target engagement from lipid mediator changes, Nrf2 signaling, and disease-relevant phenotypes.
-
HyperPFU™ high-fidelity DNA polymerase Guide
2026-09-07
HyperPFU™ high-fidelity DNA polymerase is intended for accurate amplification of long, GC-rich, or otherwise difficult DNA templates when blunt-ended products are acceptable. It should not be selected as the default enzyme for workflows requiring 3′-A overhangs, pre-formed sticky ends, or an unvalidated universal PCR recipe.
-
Sisomicin Activity Against Clinical Bacterial Isolates
2026-09-05
Stewart and Bodey evaluated sisomicin against 565 clinical isolates and found broad in vitro activity against gram-negative bacilli and gram-positive cocci, with performance generally comparable to or better than established aminoglycosides. The study is valuable as an early comparative susceptibility benchmark, while its historical isolate set and MIC-only design limit direct translation to current clinical treatment decisions.
-
BAY-826: Mapping Retinal Angiopoietin Signaling
2026-09-04
BAY-826 is a potent small molecule inhibitor that can serve as a carefully controlled perturbation tool in retinal angiopoietin and PEDF studies. This article explains how to distinguish direct pathway effects from Müller cell-mediated changes, building beyond conventional compound workflow summaries.
-
N6-Methyl-dATP as a Functional DNA Probe
2026-09-04
N6-Methyl-dATP enables controlled analysis of polymerase substrate recognition, replication fidelity, and methylation-dependent DNA interactions. This article connects the reagent to AML assay design while distinguishing direct evidence from promising experimental applications.
-
HyperPFU™ High-Fidelity DNA Polymerase Guide
2026-09-03
HyperPFU™ high-fidelity DNA polymerase is intended for accurate PCR amplification of long, GC-rich, inhibitor-affected, or otherwise difficult DNA templates. It is appropriate for blunt-ended cloning, sequencing, and sequence-critical workflows, but not for protocols that require 3′-A overhangs or sticky ends.
-
CFTRinh-172 Workflows for CFTR Inhibition
2026-09-03
CFTRinh-172 enables fast, reversible functional blockade of CFTR in epithelial transport assays, helping distinguish channel activity from changes in membrane abundance. This practical guide connects cell-based workflows with cystic fibrosis research, secretory disease models, and trafficking studies while emphasizing controls, formulation, and troubleshooting.
-
Epoxomicin: Mechanism and Research Workflow
2026-09-02
Epoxomicin is a selective, irreversible proteasome inhibitor used to interrogate protein degradation and ubiquitin-proteasome pathway research. Its α',β'-epoxyketone group supports covalent proteasome engagement, while the A2606 product information reports a 4 nM IC50 for chymotrypsin-like activity.
-
Epoxomicin for ER Stress and Proteasome Flux
2026-09-02
Epoxomicin is a selective, irreversible proteasome inhibitor for connecting protein degradation measurements with ER-stress biology. This guide explains how to use it to distinguish proteasome-dependent clearance from upstream ubiquitination and stress-sensor regulation.